VBVienna E. Brunt

Vienna E. Brunt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vienna E. Brunt has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment

    by Ravinandan Venkatasubramanian, Sophia A. Mahoney, David A. Hutton, Nicholas S. VanDongen, Vienna E. Brunt, Nathan T. Greenberg, Abigail G. Longtine, Lukas Brandt, Andreas M. Beyer, Simon Melov, et al.

    We demonstrate that cellular senescence contributes to doxorubicin-related vascular endothelial dysfunction and establishes efficacy for the use of senolytic therapy to improve vascular function following doxorubicin administration. Mechanistically, we found that cellular senescence reduced NO bioavailability and promoted excessive production of vascular mitochondrial superoxide-related oxidative stress, both of which were prevented with senolytic therapy. We translated these findings to humans and showed that ex vivo exposure to doxorubicin impaired arteriole endothelial function, which was prevented with senolytic exposure.


  • Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress

    by Ravinandan Venkatasubramanian, Mary A. Darrah, Sophia A. Mahoney, David A. Hutton, Grace S. Maurer, Katelyn R. Ludwig, Nicholas S. Van Dongen, Nathan T. Greenberg, Abigail G. Longtine, Vienna E. Brunt, et al.

    BACKGROUND: Mechanisms underlying doxorubicin chemotherapy-induced aortic stiffening are incompletely understood. To determine the role of cellular senescence and the senescence-associated secretory phenotype (SASP) in mediating doxorubicin-induced aortic stiffening and the influence of senolytic therapy. METHODS: Aortic stiffness (aortic pulse wave velocity) and associated mechanisms were assessed in young adult p16-3MR mice, a model that allows for genetic-based clearance of senescent cells with ganciclovir. Young (4–6 months) mice were injected with doxorubicin and subsequently treated with ganciclovir or the senolytic ABT263. We evaluated the influence of SASP-associated circulating factors in plasma (the circulating SASP milieu) in mediating aortic stiffening ex vivo (aortic elastic modulus) and examined the contribution of glycation stress. RESULTS: Doxorubicin increased aortic pulse wave velocity (425±6 versus control, 353±5 cm/s; P P P =0.02 versus plasma from control mice), whereas plasma from doxorubicin-ganciclovir and doxorubicin-ABT263 groups did not. Glycation stress was implicated in SASP-mediated aortic stiffening with doxorubicin, as inhibition of receptor-mediated glycation stress signaling attenuated plasma-induced aortic stiffening. CONCLUSIONS: Cellular senescence and the circulating SASP milieu contribute to doxorubicin-induced aortic stiffening. Senolytics hold promise for preserving aortic stiffening following doxorubicin exposure.


  • Exogenous estradiol increases cardiovagal baroreflex sensitivity during a hypertensive stimulus in premenopausal young women

    by Rauchelle E. Richey, Jennifer A. Miner, Jonathon C. Miner, Vienna E. Brunt, Paul F. Kaplan, John R. Halliwill, Christopher T. Minson

    Attenuated cardiovagal baroreflex sensitivity is associated with cardiovascular disease. Female sex hormones have a significant impact on the development of cardiovascular disease across the lifespan. Using an experimental model of hormone suppression and add-back, estradiol add-back alone increased cardiovagal baroreflex sensitivity to a hypertensive stimulus unlike the other hormone manipulation conditions. These data suggest that estradiol alone plays a significant role in cardiovagal baroreflex sensitivity and reductions may contribute to potential cardiovascular disease development.


  • Top Cited Papers

    Endothelial dysfunction in chronic kidney disease: a clinical perspective

    by Monique E. Cho, Vienna E. Brunt, Yan-Ting Shiu, Kanokwan Bunsawat

    Chronic kidney disease (CKD) is a progressive, multisystemic disorder that augments the risks of cardiovascular (CV) morbidity and mortality as kidney function declines. The endothelium plays a key role in modulating vascular tone, integrity, and homeostasis by producing and releasing a variety of endothelium-derived relaxing factors, including nitric oxide (NO). Endothelial dysfunction is a salient pathogenic mechanism underlying the development and progression of CKD and is characterized by reduced production of vasodilators and increased production of vasoconstrictors (e.g., endothelin-1). Factors such as the uremic milieu, inflammation, and oxidative stress are putative contributors of endothelial dysfunction and reduced NO bioavailability that ultimately impact functional and structural integrity of the vasculature. Because endothelial dysfunction is an independent predictor of CV morbidity and mortality in patients with CKD, several clinical studies have examined disease-related changes in endothelium-dependent vasodilation across the arterial tree. This review will focus on the clinical evidence regarding CKD-associated endothelial dysfunction involving both the micro- and macrovasculature, briefly discussing underlying physiological mechanisms, and summarizing available and emerging pharmacotherapies along with a brief summary of exercise training as a lifestyle intervention.


  • Open Access

    The bottlenose dolphin (Tursiops truncatus): a novel model for studying healthy arterial aging

    by Yara Bernaldo de Quirós, Sophia A. Mahoney, Nicholas S. VanDongen, Nathan T. Greenberg, Ravinandan Venkatasubramanian, Pedro Saavedra, Greg Bossart, Vienna E. Brunt, Zachary S. Clayton, Antonio Fernández, et al.

    We demonstrate that, unlike serum of midlife/older adult humans, age-matched dolphin serum elicits higher endothelial function ex vivo in young mouse carotid arteries, suggesting that the circulating milieu of bottlenose dolphins may be geroprotective. We propose that dolphins are a novel model to investigate potential novel therapeutic strategies to mitigate age-related endothelial dysfunction in humans.


  • Open Access

    Oral Supplementation with the Short-Chain Fatty Acid Acetate Ameliorates Age-Related Arterial Dysfunction in Mice

    by Vienna E. Brunt, Abigail G. Longtine, Nathan T. Greenberg, Antonio Gonzalez, Alexandra Lindquist, Nicholas S. VanDongen, Sophia A. Mahoney, Gibraan Rahman, Zachary S. Clayton, Brian P. Ziemba, et al.

    Our mission is to publish high quality research on the fundamental mechanisms of aging and longevity.


  • Open Access

    Role of the circulating milieu in age-related arterial dysfunction: a novel ex vivo approach

    by Sophia A. Mahoney, Nicholas S. VanDongen, Nathan T. Greenberg, Ravinandan Venkatasubramanian, Matthew J. Rossman, Michael E. Widlansky, Vienna E. Brunt, Yara Bernaldo de Quirós, Douglas R. Seals, Zachary S. Clayton

    Changes in the circulating milieu with advancing age may be a mechanism underlying age-related arterial dysfunction. Ex vivo exposure of young mouse arteries to the circulating milieu from old mice or midlife/older adults impairs arterial function whereas exposure of old mouse arteries to the circulating milieu from young mice or young adults improves arterial function. These findings establish that the circulating milieu directly influences arterial function with aging.


  • The gut microbiome as a modulator of arterial function and age-related arterial dysfunction

    by Abigail G. Longtine, Nathan T. Greenberg, Yara Bernaldo de Quirós, Vienna E. Brunt

    The arterial system is integral to the proper function of all other organs and tissues. Arterial function is impaired with aging, and arterial dysfunction contributes to the development of numerous age-related diseases, including cardiovascular diseases. The gut microbiome has emerged as an important regulator of both normal host physiological function and impairments in function with aging. The purpose of this review is to summarize more recently published literature demonstrating the role of the gut microbiome in supporting normal arterial development and function and in modulating arterial dysfunction with aging in the absence of overt disease. The gut microbiome can be altered due to a variety of exposures, including physiological aging processes. We explore mechanisms by which the gut microbiome may contribute to age-related arterial dysfunction, with a focus on changes in various gut microbiome-related compounds in circulation. In addition, we discuss how modulating circulating levels of these compounds may be a viable therapeutic approach for improving artery function with aging. Finally, we identify and discuss various experimental considerations and research gaps/areas of future research.


  • Top Cited Papers
    Open Access

    Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence

    by Sophia A. Mahoney, Ravinandan Venkatasubramanian, Mary A. Darrah, Katelyn R. Ludwig, Nicholas S. VanDongen, Nathan T. Greenberg, Abigail G. Longtine, David A. Hutton, Vienna E. Brunt, Judith Campisi, et al.

    Cellular senescence and the senescence‐associated secretory phenotype (SASP) contribute to age‐related arterial dysfunction, in part, by promoting oxidative stress and inflammation, which reduce the bioavailability of the vasodilatory molecule nitric oxide (NO). In the present study, we assessed the efficacy of fisetin, a natural compound, as a senolytic to reduce vascular cell senescence and SASP factors and improve arterial function in old mice. We found that fisetin decreased cellular senescence in human endothelial cell culture. In old mice, vascular cell senescence and SASP‐related inflammation were lower 1 week after the final dose of oral intermittent (1 week on—2 weeks off—1 weeks on dosing) fisetin supplementation. Old fisetin‐supplemented mice had higher endothelial function. Leveraging old p16‐3MR mice, a transgenic model allowing genetic clearance of p16INK4A‐positive senescent cells, we found that ex vivo removal of senescent cells from arteries isolated from vehicle‐ but not fisetin‐treated mice increased endothelium‐dependent dilation, demonstrating that fisetin improved endothelial function through senolysis. Enhanced endothelial function with fisetin was mediated by increased NO bioavailability and reduced cellular‐ and mitochondrial‐related oxidative stress. Arterial stiffness was lower in fisetin‐treated mice. Ex vivo genetic senolysis in aorta rings from p16‐3MR mice did not further reduce mechanical wall stiffness in fisetin‐treated mice, demonstrating lower arterial stiffness after fisetin was due to senolysis. Lower arterial stiffness with fisetin was accompanied by favorable arterial wall remodeling. The findings from this study identify fisetin as promising therapy for clinical translation to target excess cell senescence to treat age‐related arterial dysfunction.